Solid Biosciences Provides Letter to the Duchenne Community: Data and IGNITE DMD Clinical Trial Update
Solid Biosciences Inc. provided an update on the IGNITE DMD phase I/II microdystrophin gene therapy clinical program. Solid shares that biomarker data from all three patients dosed in the 2E14 vg/kg cohort of IGNITE DMD…Learn More